Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Pacmilimab · CX-072, CX-072 PROBODY

Monoclonal antibody · Immune activation, directed at programmed cell death 1 ligand 1 (CD274) · developed by CytomX Therapeutics

Phase 2 Most advanced trial (none active)
CTMX Developer
1 Registered trials

What is Pacmilimab?

Pacmilimab is a recombinant antibody prodrug whose anti-PD-L1 antibody is masked by a peptide linked through a protease-cleavable linker. Tumor-associated proteases cleave the mask, allowing the active antibody to bind PD-L1 and block its interaction with PD-1 on T-cells. It is studied in solid tumors and unresectable or metastatic melanoma, including in combination with ipilimumab.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
CX-072, CX-072 PROBODY
Drug type
Monoclonal antibody
Targets
programmed cell death 1 ligand 1 (CD274), programmed cell death 1 (PDCD1) (binding partner it blocks)
Mechanism
Immune activation, directed at programmed cell death 1 ligand 1 (CD274)
Pathways
PD-1/PD-L1 immune checkpoint signaling, T-cell activation
Therapy area
Oncology
Developer
CytomX Therapeutics (CTMX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
ZXP96ZI2RA

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03993379 Phase 2 Solid Tumor Terminated CTMX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Solid TumorUnresectable or Metastatic Melanoma

Other drugs acting on CD274

More from CytomX Therapeutics

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the CTMX page.

Follow CTMX, the company behind Pacmilimab

See CTMX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CTMX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.